Yes, hepatitis B can kill you, but whether it does depends heavily on the type of infection, whether it becomes chronic, and whether you receive treatment. Globally, hepatitis B caused an estimated 1.1 million deaths in 2022, almost all from cirrhosis and liver cancer. The good news: with modern antiviral therapy, people with chronic hepatitis B can live just as long as the general population.
How Hepatitis B Becomes Fatal
Hepatitis B kills through two main pathways, and both involve long-term damage rather than the initial infection itself. The virus triggers ongoing inflammation in the liver, which over years causes scar tissue to replace healthy tissue. This scarring process, called fibrosis, eventually leads to cirrhosis, where the liver is so damaged it can no longer function properly. Without treatment, 2 to 10% of people with chronic hepatitis B develop cirrhosis each year.
The second pathway is liver cancer. Between 25 and 40% of people who carry the virus long-term will develop hepatocellular carcinoma, the most common form of liver cancer. Overall, roughly 25% of untreated chronic hepatitis B patients die from cirrhosis, liver cancer, or both. That number rises to 50% in men, who face higher rates of both complications.
The Acute Infection Risk
Most adults who catch hepatitis B clear the virus on their own within six months. But in about 1% of acute cases, the immune response spirals into what’s called fulminant hepatitis, where the liver fails rapidly. This is a medical emergency with a mortality rate near 70%. It’s rare, but it’s the reason hepatitis B can be fatal even before it becomes chronic.
Why Age at Infection Matters So Much
The younger you are when you’re infected, the more dangerous hepatitis B becomes. An infant exposed at birth without preventive treatment has a 90% chance of developing a chronic infection, one that carries a 25% lifetime risk of death from liver failure or liver cancer. Adults, by contrast, have roughly a 95% chance of clearing the virus entirely. This is why newborn vaccination programs have been one of the most effective public health interventions against hepatitis B worldwide.
Warning Signs of Serious Liver Damage
Chronic hepatitis B is often called a “silent” infection because it can damage the liver for decades without obvious symptoms. By the time symptoms appear, the disease may already be advanced. Signs that the liver is failing include persistent fatigue, swelling in the legs and ankles, itching, pain in the upper right abdomen, shortness of breath, and confusion or changes in alertness. These symptoms reflect a liver that can no longer filter toxins, manage fluid balance, or produce essential proteins.
Coinfection With Hepatitis D
Hepatitis D can only infect people who already have hepatitis B, and the combination is significantly more dangerous. In a large study of U.S. veterans, the annual death rate among coinfected individuals who weren’t receiving treatment was 5.14 per 100 person-years, compared to 2.98 for those with hepatitis B alone. That’s roughly a 70% higher mortality rate. Treatment for hepatitis B appears to narrow that gap, but coinfection remains one of the most serious risk multipliers for people living with the virus.
Treatment Changes the Outcome Dramatically
Modern antiviral medications have transformed chronic hepatitis B from a likely death sentence into a manageable condition. In an eight-year study of patients on long-term antiviral therapy, survival rates were statistically identical to the general population. The one-year survival rate was 99.7%, the five-year rate was 95.9%, and the eight-year rate was 94.1%. For patients who didn’t develop liver cancer, mortality was actually lower than average.
The difference treatment makes is stark. A large study from Taiwan tracked over 43,000 patients and found that the seven-year liver cancer rate was 7.32% in treated patients versus 22.7% in untreated patients. In cases where hepatitis B reactivates and causes acute liver failure, one trial found 90-day survival of just 15% with placebo compared to 57% with antiviral treatment.
Among untreated patients who already have cirrhosis, only 55 to 85% survive five years. With treatment, those numbers improve substantially, though people with advanced scarring still face higher risks than those who start therapy earlier.
Vaccination Prevents the Threat Entirely
The hepatitis B vaccine, given at birth or in early childhood, is one of the most effective cancer-prevention tools in medicine. A landmark study following vaccinated individuals for 37 years found that the vaccine reduced liver cancer incidence by 72%, liver cancer deaths by 70%, and deaths from liver disease overall by 64%. For anyone not yet infected, vaccination eliminates the risk almost entirely. The vaccine is now part of routine childhood immunization schedules in most countries and is available to unvaccinated adults as well.